Treatment for Enterococcus faecalis Bacteremia in Patients with Acute Kidney Injury
First-Line Treatment Options
- The Infectious Diseases Society of America recommends linezolid 600 mg IV or PO every 12 hours as the first-line treatment for enterococcal infections in patients with acute kidney injury, due to its efficacy against enterococci and minimal renal adjustment requirements 1, 2
- Treatment duration with linezolid depends on the site of infection and clinical response, typically 4-6 weeks for bacteremia 2
Alternative Treatment Options
- High-dose daptomycin (8-12 mg/kg IV daily) is recommended as an alternative for enterococcal bacteremia, with consideration of combination with β-lactams to enhance efficacy against E. faecalis 2, 3
Special Considerations for Acute Kidney Injury
- The American Heart Association recommends avoiding aminoglycoside-containing regimens in AKI due to significant nephrotoxicity risk 4, 5
Monitoring Requirements
- Regular monitoring of renal function is essential during treatment, and for patients on linezolid, monitoring of complete blood counts weekly is necessary due to potential hematologic effects with prolonged use 2, 6
Treatment Algorithm Based on Susceptibility Testing
- For penicillin-susceptible E. faecalis, linezolid 600 mg IV/PO q12h is the preferred treatment option, with adjusted-dose daptomycin as an alternative if linezolid is contraindicated 1, 2
Duration of Therapy
- The American Heart Association recommends 4 weeks of antimicrobial therapy for uncomplicated bacteremia, and 6 weeks for complicated bacteremia or endocarditis 5, 7
Important Caveats and Pitfalls
- Failure to obtain adequate source control may lead to treatment failure regardless of antibiotic choice, and prolonged linezolid therapy requires monitoring for thrombocytopenia, anemia, and peripheral neuropathy 8
- The Infectious Diseases Society of America recommends avoiding empiric use of vancomycin without susceptibility testing, as vancomycin resistance in enterococci is increasingly common 2, 9